A detailed history of Altium Capital Management LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 126,000 shares of VKTX stock, worth $5.32 Million. This represents 2.81% of its overall portfolio holdings.

Number of Shares
126,000
Previous 122,000 3.28%
Holding current value
$5.32 Million
Previous $6.47 Million 23.35%
% of portfolio
2.81%
Previous 3.44%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $199,360 - $281,880
4,000 Added 3.28%
126,000 $7.98 Million
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $1.75 Million - $2.97 Million
37,000 Added 43.53%
122,000 $6.47 Million
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $1.48 Million - $8.03 Million
85,000 New
85,000 $6.97 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.24B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.